The earnings call presented both positive developments in clinical trials and global expansion efforts, contrasted by significant declines in revenue and sales metrics. The financial challenges, including decreased revenue, prescriptions, and inventory issues, were offset by positive clinical trial results and strategic global partnerships.

Company Guidance -

Q3 2025

During the conference call for the first quarter of 2025, Puma Biotechnology provided guidance on several key financial metrics. The company reported total revenue of $46.0 million, with net product revenue from NERLYNX sales at $43.1 million, a decrease from the previous quarter but an increase from the same quarter last year. Royalty revenue for the quarter was $2.9 million. The company noted a decrease of approximately $4.7 million in inventory at specialty pharmacies and distributors. For fiscal year 2025, Puma anticipates net NERLYNX product revenue to range between $192 million and $198 million, with royalties expected between $20 million and $24 million. The gross to net adjustment for the full year is projected to be between 20.5% and 21.5%. Additionally, Puma forecasts a net income between $23 million and $28 million for the year, with no expected license revenue. For the second quarter of 2025, the company expects NERLYNX net product revenue of $48 million to $50 million and royalty revenue of $2 million to $3 million.

Increase in New Prescriptions

New prescriptions for NERLYNX were up approximately 6% compared to Q4 2024.

Expansion of Global Reach

NERLYNX was launched in Libya in the extended adjuvant setting, and a distribution agreement was signed with Er-Kim for select countries in Eastern Europe and Central Asia.

Positive Phase I Trial Data

Interim data from a Phase I trial showed promising results for the combination of neratinib and Fam-trastuzumab deruxtecan in patients with metastatic solid tumors.

Potential for Improved Patient Outcomes

The adoption of dose escalation for NERLYNX patients remains high, with approximately 72% of patients starting at a reduced dose, which is associated with better persistence and compliance.

Puma Biotechnology (PBYI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PBYI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.04 / -	0.41	―	―	―
Aug 07, 2025	2025 (Q2)	0.09 / 0.12	-0.09	233.33% (+0.21)
May 08, 2025	2025 (Q1)	-0.02 / 0.06	-0.1	160.00% (+0.16)
Feb 27, 2025	2024 (Q4)	0.09 / 0.39	0.26	50.00% (+0.13)
Nov 07, 2024	2024 (Q3)	0.33 / 0.41	0.12	241.67% (+0.29)
Aug 01, 2024	2024 (Q2)	-0.13 / -0.09	0.05	-280.00% (-0.14)
May 02, 2024	2024 (Q1)	-0.22 / -0.10	0.03	-433.33% (-0.13)
Feb 29, 2024	2023 (Q4)	0.30 / 0.26	-0.12	316.67% (+0.38)
Nov 02, 2023	2023 (Q3)	0.08 / 0.12	-0.01	1300.00% (+0.13)
Aug 03, 2023	2023 (Q2)	0.01 / 0.05	0.21	-76.19% (-0.16)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PBYI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$3.29	―	―
May 08, 2025	$3.07	$2.91	-5.21%
Feb 27, 2025	$2.99	$3.58	+19.73%
Nov 07, 2024	$3.03	$2.88	-4.95%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Puma Biotechnology (PBYI) report earnings?

Puma Biotechnology (PBYI) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Puma Biotechnology (PBYI) earnings time?

Puma Biotechnology (PBYI) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PBYI EPS forecast?

PBYI EPS forecast for the fiscal quarter 2025 (Q3) is 0.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing